Journal
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume 35, Issue 6, Pages 398-403Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/cbr.2019.3188
Keywords
F-18 choline; metastatic castration-resistant prostate cancer; PET-CT; (223)Radium dichloride; targeted alpha therapy; total lesion activity
Ask authors/readers for more resources
The aim of the study was to assess the correlation between metabolic response measured through positron emission tomography-computed tomography (PET-CT) with(18)F choline (F-18 FCH) and overall survival (OS) in patients affected by bone lesions from metastatic castration-resistant prostate cancer treated with(223)Ra dichloride. Eleven subjects were subjected to PET-CT with(18)F FCH before and 1 month after(223)Ra treatment. Reduction in total lesion activity (Delta TLA) between pretreatment and post-treatment scan was determined and patients were divided into responders (Delta TLA >50%) and nonresponders (Delta TLA <50%). The OS of the entire cohort was 12.7 +/- 3.8 months. Kaplan-Meier analysis showed that responders presented a significantly longer survival than nonresponders (16.5 +/- 1.9 months vs. 10.5 +/- 0.9 months,p < 0.05). Reduction in TLA after(223)Ra treatment seems to be correlated with a trend toward a longer survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available